Implantable Medical-Grade Primary Lithium Batteries

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

75F40126Q00420

NAICS

335910 - Battery Manufacturing

Classification Code

6135

Additional Details
Set Aside

NONE

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
Documents3
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a solicitation for the procurement of implantable medical-grade primary lithium batteries. This requirement, identified under procurement number 75F40126Q00420, seeks to acquire a total of twenty (20) new and unused lithium batteries of Li/SVO-CFx chemistry, divided into two distinct configurations of ten (10) units each. The batteries are intended for use in medical implant applications, supporting the FDA’s mission to ensure the safety and efficacy of medical devices. The scope of this procurement encompasses the supply of both high-rate and medium-rate battery configurations, each with stringent technical and quality requirements. For the high-rate configuration (Item 1), the batteries must have a rated capacity between 1.70 Ah and 1.90 Ah (nominal 1.78 Ah), an open-circuit voltage at beginning of life (OCV-BOL) between 3.15 V and 3.40 V (nominal 3.25 V), and be capable of pulse discharge with a continuous background load of at least 95.3 kΩ, pulse amplitude of at least 3.0 A, pulse duration of 10 seconds, and pulse frequency up to once every 150 days, with a cutoff voltage of 2.0 V. The batteries must feature a stainless steel case, negative case polarity, molybdenum or equivalent terminal, hermetic sealing, a maximum weight of 17 grams, and a maximum volume of 6.5 cc. Physical dimensions are specified as approximately 34.93 mm × 27.94 mm × 6.30 mm, not to exceed these values by more than 5%. Storage temperature must range from –20°C to +60°C. All ten units must originate from the same manufacturing lot. For the medium-rate configuration (Item 2), the batteries are required to have a rated capacity between 4.80 Ah and 5.00 Ah (nominal 4.92 Ah), OCV-BOL between 3.15 V and 3.40 V (nominal 3.25 V), and be capable of medium-rate sustained discharge with pulsing (background load 9.53 kΩ, pulse amplitude 20 mA, pulse duration 900 seconds, pulse frequency up to once every 63 days, cutoff voltage 2.0 V minimum). Usable capacity must be maintained between OCV-BOL and cutoff at 37°C. These batteries must have a titanium case, negative case polarity, titanium or equivalent terminal, hermetic sealing, a maximum weight of 22 grams, and a maximum volume of 12.5 cc. Dimensions are approximately 46.48 mm × 31.70 mm × 9.63 mm, not to exceed these values by more than 5%. The nominal operating temperature is 37°C, with storage temperature requirements matching those of the high-rate configuration. All ten units must also be from the same manufacturing lot. Across both configurations, each battery must have a minimum of two years remaining from the date of manufacture at the time of delivery. Required deliverables include comprehensive product documentation such as battery specifications, safety data sheets (SDS), and any other applicable documentation, all provided at no additional charge. Packaging must adhere to standard commercial practices and comply with all relevant safety and transportation regulations for lithium-based medical-grade components, including Department of Transportation (DOT) and International Air Transport Association (IATA) Dangerous Goods Regulations. Each package must be clearly marked with the lot number and date of manufacture. Advance shipping notification is required, including carrier details, tracking information, and estimated delivery date, with delivery logistics to be coordinated with the designated Government point of contact prior to shipment. The Government will accept the contractor’s standard commercial warranty to the maximum extent practicable. Notably, these batteries are passive supply items with no embedded or companion software, no FDA network connection, and no data storage or transmission capabilities. The procurement is classified under NAICS code 335910 (Battery Manufacturing, 2022 version) and Product Service Code 6135. There are no set-aside restrictions for this solicitation. The place of performance is Silver Spring, Maryland, United States. The contracting activity is managed by the FDA Office of Acquisition and Grant Services. Interested parties may direct inquiries to the primary contact, Reagan Davis, via email at [email protected] or by phone at 301-796-0910. The solicitation was posted on October 9, 2026, with responses due by September 15, 2026. The opportunity remains active and further details, including attachments, can be accessed via the official SAM.gov listing at https://sam.gov/opp/a8190b52ce7049c5ba1edcdf9537ee4f/view. This procurement represents a specialized opportunity for manufacturers and suppliers of implantable medical-grade lithium batteries who can meet the FDA’s rigorous technical, quality, and regulatory requirements. Contractors should carefully review the full solicitation and requirements document to ensure alignment with their capabilities and compliance with all specified criteria.